Mewton N, Roubille F, Bresson D, et al. - Findings from this randomized, placebo-controlled trial suggest no reduction in infarct size (IS) as assessed by cardiac magnetic resonance imaging in correlation with oral administration of high-dose colchicine at the time of reperfusion and for 5 days.

• Enrolled were a total of 192 patients admitted for a first episode of ST segment–elevation myocardial infarction referred for primary percutaneous coronary intervention.

• The colchicine and placebo groups showed no significant differences in terms of the gadolinium enhancement–defined IS at 5 days, LV remodeling at 3 months follow-up and infarct size at 3 months.

• With colchicine, greater incidence of gastrointestinal adverse events were recorded during the treatment period than with placebo.